Medivation, Orexigen Highlight Late-Stage Strategies for Closely-Watched Drugs
This article was originally published in The Pink Sheet Daily
Medivation will push on with Phase III trials despite an Alzheimer's failure, while Orexigen says a competitor's obesity drug could affect partnering plans.
You may also be interested in...
A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.
FDA tells the biotech corrections to secondary endpoint data for one pivotal study for its diet pill filing comprise only a clinical amendment.
The drug's inability to show an efficacy benefit highlights risks of Alzheimer's disease drug development and pressures Pfizer to pull off some pipeline wins.